Elk Creek Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Elk Creek Partners’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$13.4M	Buy	46,663 +15,976	+52%	+$4.41M	2.31%	7
2019 Q4	$8.82M	Sell	30,687 -54,028	-64%	-$11.7M	1.01%	40
2019 Q3	$12.2M	Buy	+84,715	New	+$11.5M	1.05%	28

Other funds holding KPTI

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Elk Creek Partners's KPTI Position: Q1 2020 in Review

Elk Creek Partners increased its Karyopharm Therapeutics (KPTI) stake by 52% in Q1 2020, buying an estimated $4.41M and bringing the position to 46,663 shares worth $13.4M. The position accounts for 2.31% of the portfolio, ranked #7.

Elk Creek Partners first reported a position in KPTI in Q3 2019 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

Elk Creek Partners held 46,663 shares of Karyopharm Therapeutics worth $13.4M as of Q1 2020.
Elk Creek Partners bought 15,976 Karyopharm Therapeutics shares in Q1 2020, an estimated $4.41M.
Karyopharm Therapeutics made up 2.31% of Elk Creek Partners's portfolio in Q1 2020, its #7 holding.
Elk Creek Partners first reported a position in Karyopharm Therapeutics in Q3 2019 and has held it in 3 quarters since.
136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.